Cargando…

Relations of physical signs to genotype, lipid and inflammatory markers, coronary stenosis or calcification, and outcomes in patients with heterozygous familial hypercholesterolemia

BACKGROUND: Although the presence of physical signs [tendon xanthomas and/or corneal arcus (TX/CA)], are associated with the risk of coronary artery disease in patients with heterozygous familial hypercholesterolemia (HeFH), their relationship with genotypes and clinical characteristics has not been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Ming-Ming, Peng, Jia, Guo, Yuan-Lin, Zhu, Cheng-Gang, Wu, Na-Qiong, Xu, Rui-Xia, Dong, Qian, Li, Jian-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650321/ https://www.ncbi.nlm.nih.gov/pubmed/34876165 http://dx.doi.org/10.1186/s12967-021-03166-w

Ejemplares similares

Correlates of Coronary Artery Calcification Prevalence and Severity in Patients With Heterozygous Familial Hypercholesterolemia
por: Drouin-Chartier, Jean-Philippe, et al.
Publicado: (2020)

Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
por: McGowan, Mary P., et al.
Publicado: (2019)

Genetic screening for homozygous and heterozygous familial hypercholesterolemia
por: Izar, Maria C, et al.
Publicado: (2010)

Ostial Coronary Stenosis and Severe Aortic Stenosis in a Patient With Familial Hypercholesterolemia
por: Kaya, Hasan, et al.
Publicado: (2012)

Genotype–phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia
por: Reijman, M.D., et al.
Publicado: (2023)

Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia
por: Ershova, Alexandra I., et al.
Publicado: (2016)

Aortic Valvular Disease in Elderly Subjects with Heterozygous Familial Hypercholesterolemia: Impact of Lipid-Lowering Therapy
por: Marco-Benedí, Victoria, et al.
Publicado: (2019)

Implementation of Novel Lipid Therapies in a Refractory Heterozygous Familial Hypercholesterolemia Patient With Atherosclerotic Disease
por: Weintraub, Spencer F., et al.
Publicado: (2022)

Role of colesevelam in managing heterozygous familial hypercholesterolemia in adolescents and children
por: Sonnett, Travis, et al.
Publicado: (2010)

Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside
por: Agarwala, Anandita, et al.
Publicado: (2021)

Awareness and knowledge of heterozygous familial hypercholesterolemia among Serbian pediatricians
por: Bjelakovic, Ljiljana, et al.
Publicado: (2023)

Prevalent Coronary Artery Disease and Undertreatment in Heterozygous Familial Hypercholesterolemia -Real-World Data and “Heterozygous FH Score” from FAME Study-
por: Nohara, Atsushi
Publicado: (2022)

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)
por: Sudano, Isabella, et al.
Publicado: (2022)

SORBS2 as a molecular target for atherosclerosis in patients with familial hypercholesterolemia
por: Liu, Ming-Ming, et al.
Publicado: (2022)

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
por: Ginsberg, Henry N., et al.
Publicado: (2019)

Cascade Screening and Treatment Initiation in Young Adults with Heterozygous Familial Hypercholesterolemia
por: Peterson, Amy L., et al.
Publicado: (2021)

Familial Hypercholesterolemia: The Lipids or the Genes?
por: Fahed, Akl C, et al.
Publicado: (2011)

Impact of Diet on Plasma Lipids in Individuals with Heterozygous Familial Hypercholesterolemia: A Systematic Review of Randomized Controlled Nutritional Studies
por: Roy, Gabrielle, et al.
Publicado: (2021)

Cholesterol Metabolic Markers for Differential Evaluation of Patients with Hyperlipidemia and Familial Hypercholesterolemia
por: Li, Zhi-Zhao, et al.
Publicado: (2022)

Familial hypercholesterolemia supravalvular aortic stenosis and extensive atherosclerosis
por: Prajapati, Rajpal, et al.
Publicado: (2018)

Cataract Surgery in Elderly Subjects with Heterozygous Familial Hypercholesterolemia in Prolonged Treatment with Statins
por: Marco-Benedí, Victoria, et al.
Publicado: (2021)

How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?
por: Kataoka, Yu, et al.
Publicado: (2022)

Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey
por: Yao, Hermann, et al.
Publicado: (2021)

An update on lipid apheresis for familial hypercholesterolemia
por: Taylan, Christina, et al.
Publicado: (2022)

Coronary Artery Calcification as a Marker for Coronary Artery Stenosis: Comparing Kidney Failure to the General Population
por: Jansz, Thijs T., et al.
Publicado: (2021)

LDL apheresis in a woman with severe heterozygous familial hypercholesterolemia. Late, but not too late
por: Mickiewicz, Agnieszka, et al.
Publicado: (2015)

Long‐Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening
por: Kjærgaard, Kasper Aalbæk, et al.
Publicado: (2017)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives
por: Catapano, Alberico Luigi, et al.
Publicado: (2017)

Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters
por: Vuorio, Alpo, et al.
Publicado: (2018)

Myocardial strain impairment, heterozygous familial hypercholesterolemia and systemic arterial hypertension: Is there a link?
por: Vitarelli, Antonio
Publicado: (2021)

Estimated Yield of Screening for Heterozygous Familial Hypercholesterolemia With and Without Genetic Testing in US Adults
por: Bellows, Brandon K., et al.
Publicado: (2022)

Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemia
por: Ferrières, Jean, et al.
Publicado: (2022)

Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
por: Matta, Anthony, et al.
Publicado: (2023)

Early echocardiographic signs of cardiovascular affection in pediatric familial hypercholesterolemia
por: Ibrahim, Hossam, et al.
Publicado: (2023)

A 72-Year-Old Patient with Longstanding, Untreated Familial Hypercholesterolemia but no Coronary Artery Calcification: A Case Report
por: Johnson, Kipp W, et al.
Publicado: (2018)

Usefulness of Lipid Apheresis in the Treatment of Familial Hypercholesterolemia
por: Lui, Matthew, et al.
Publicado: (2014)

A Case of Severe Carotid Stenosis in a Patient with Familial Hypercholesterolemia without Significant Coronary Artery Disease
por: Barros, Marcos Aurélio Lima, et al.
Publicado: (2014)

Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia
por: Parhofer, Klaus G
Publicado: (2012)

An Eight-Week Trial Investigating the Efficacy and Tolerability of Atorvastatin for Children and Adolescents With Heterozygous Familial Hypercholesterolemia
por: Gandelman, Kuan, et al.
Publicado: (2011)

Heterozygous Familial Hypercholesterolemia With APOE Haplotype: A Prospective Harbinger of a Catastrophic Cardiovascular Event
por: Lasam, Glenmore, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_go5eedpubaaeu2e0cecoqn8jjs